市場調查報告書
商品編碼
1497773
生物晶片市場:按類型、製造技術、應用和最終用戶分類 - 全球預測 2024-2030Biochips Market by Type (Arrays, DNA Chips, Lab-On-A-Chip), Fabrication Technology (Microarrays, Microfluidics), Application, End-User - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年生物晶片市場規模為202.9億美元,預計2024年將達241億美元,2030年將達到704億美元,複合年成長率為19.44%。
生物晶片是放置在固體基板上的微觀測試位點的集合,並透過同時執行多個測試來實現高通量和速度。生物晶片應用於多種領域,包括醫學和藥物研究、疾病診斷、藥物發現、農業科學和環境保護。危及生命的疾病的日益流行和老年人口的增加正在推動生物晶片市場的成長。此外,由於生物技術領域的進步和生物晶片的採用增加,對個人化採用的需求不斷成長。然而,生物晶片產品的高額初始投資正在阻礙市場成長。此外,新興國家不利的報銷情況和對該技術缺乏認知正在阻礙市場的全部潛力。此外,該領域的持續發展(例如奈米生物晶片)正在為該行業的風險投資公司和潛在先驅者創造充滿希望的機會。探索微陣列技術的進步、透過消除雜訊來提高資料品質以及透過小型化增強生物晶片功能是其中的一些途徑。
主要市場統計 | |
---|---|
基準年[2023] | 202.9億美元 |
預測年份 [2024] | 241億美元 |
預測年份 [2030] | 704億美元 |
複合年成長率(%) | 19.44% |
區域洞察
美國和加拿大佔據美洲生物晶片市場的很大佔有率。隨著醫療保健領域,特別是個人化醫療和基因研究的大量投資,生物晶片的應用範圍顯然正在擴大。特別是個人化醫療和基因研究的投資活躍,生物晶片的使用範圍正在擴大。美洲是生物晶片製造中心,持有眾多專利,展現了生物晶片技術的領先地位。在 EMEA(歐洲、中東和非洲)地區,歐盟國家憑藉其先進的醫療設施、不斷提高的醫療保健意識和龐大的醫療保健預算,為生物晶片市場做出了巨大貢獻。此外,歐盟也促進生物技術產業投資,支持生物晶片領域的研究與創新。這種支援包括為眾多計劃提供資金以及生物晶片技術的專利權。相較之下,中東和非洲雖然經濟新興,但尚未充分發揮生物晶片市場的潛力。然而,人們越來越認知到生物晶片在有效疾病診斷和個人化醫療方面的優勢,預計該地區將出現成長。由於慢性病的增加和製藥業的強勁成長,亞太地區對生物晶片的需求不斷增加,特別是在中國、日本和印度。在醫療保健技術,特別是生物晶片方面有大量投資。
FPNV定位矩陣
FPNV定位矩陣對於評估供應商在生物晶片市場的定位至關重要。此矩陣提供了對供應商的全面評估,並檢驗了與業務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可對生物晶片市場供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻,您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外,該分析還提供了對該行業競爭力的寶貴見解,包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。
策略分析與建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對目前在生物晶片市場中的地位進行全面評估,使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。
[182 Pages Report] The Biochips Market size was estimated at USD 20.29 billion in 2023 and expected to reach USD 24.10 billion in 2024, at a CAGR 19.44% to reach USD 70.40 billion by 2030.
A biochip is a collection of microscopic test sites arranged on a solid substrate that allows many tests to be performed simultaneously to achieve higher throughput and speed. Biochips are used in various fields, including medical and pharmaceutical research, disease diagnostics, drug discovery, agricultural science, and environmental protection. The growing prevalence of life-threatening disorders and the rise in the geriatric population are driving the growth of the biochips market. Moreover, advancements in the biotechnology sector along with the growing demand for personalized adoption owing to increased adoption of biochips. However, the high cost of biochip products, coupled with the requirement of high initial investment, hampers the market growth. Additionally, unfavorable reimbursement scenarios and a lack of awareness of this technology in developing countries inhibit the market's full potential. Furthermore, the continuous developments in the field, such as nano-biochips, are creating promising opportunities for venturing businesses and potential pioneers in the industry. Exploring advancements in microarray technology, improving data quality via noise removal, and enhancing biochip functional capabilities through miniaturization are a few such avenues.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 20.29 billion |
Estimated Year [2024] | USD 24.10 billion |
Forecast Year [2030] | USD 70.40 billion |
CAGR (%) | 19.44% |
Regional Insights
The United States and Canada hold a significant share of the biochip market in the Americas; with heavy investments in the healthcare sector, especially in personalized medicine and genetic research, an increasing scope for biochip usage is evident. The Americas, being the hub of significant biochip manufacturers, holds numerous patents depicting its leadership in biochip technology. In the EMEA region, EU countries significantly contribute to the biochips market due to advanced medical facilities, heightened healthcare awareness, and substantial healthcare budgets. Additionally, the EU has stimulated investments in the Biotech industry, empowering research and innovation in the biochip field. This support includes funding for numerous projects and patent rights for biochip technology. In contrast, the Middle East and Africa, while rising on the economic front, are yet to fully embrace the potential of the biochip market. However, there is a growing awareness about the advantages of biochips in effective disease diagnosis and personalized medicine, indicating prospective growth in the region. The Asia Pacific region, particularly China, Japan, and India, has shown an increasing demand for biochips due to the rising chronic diseases prevalence and the robust growth of the pharmaceutical sector. Significant investment has been made in healthcare technologies, specifically in biochips.
Market Insights
The market dynamics represent an ever-changing landscape of the Biochips Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Biochips Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Biochips Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Archer's First-Generation Biochip gFET Design Validated by Joint Fabrication with a Foundry Partner
Archer Materials Limited, a semiconductor company that manufactures Biochip graphene field effect transistors, has successfully validated its first-generation gFET design through a Multi-Project Wafer obtained from an external German foundry partner. This collaboration marks the first joint fabrication between Archer and an external foundry partner, as the final fabrication processes were conducted in-house by the Company in Australia. The gFETs produced by the MPW have been proven to function as expected, including the demonstration of liquidgating, and are compatible with the Archer Biochip system platform. [Published On: 2023-11-09]
Opteev Files Patent for New Multiplex Biochip
Opteev Technologies has recently filed a patent for a groundbreaking multiplex biochip. This innovative polymer-based biochip has the capability to rapidly and accurately detect various respiratory pathogens like Flu, SARS-CoV-2, and RSV. With a remarkable accuracy rate of 99.49%, this biochip can detect complete viruses in samples such as nasal swabs or saliva within just one minute. The introduction of this technology is expected to bring numerous benefits to healthcare providers. [Published On: 2023-08-01]
Nutcracker Therapeutics Raises $167 Million in Series C Financing to Advance its mRNA Therapeutics and First-of-its-Kind Biochip-based Manufacturing Platform
Nutcracker Therapeutics, a biotech company, has successfully raised USD 167 million in Series C financing. This funding supports the expansion and advancement of Nutcracker's pipeline of mRNA medicines for cancer and the refinement of their RNA manufacturing platform and underlying technology. The company's unique approach combines RNA biochemistry, microfluidic engineering, semiconductor-such as biochips, and a proprietary nanoparticle delivery technology, resulting in an automated and isolated manufacturing pathway. [Published On: 2022-03-14]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Biochips Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Biochips Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, ACROBiosystems Inc., Agilent Technologies, Inc., Archer Materials Limited, Bio-Rad Laboratories, Inc., BioMerieux SA, Cellix Ltd. by Randox Laboratories Ltd., Diagnostic Biochips, Inc, F. Hoffmann-La Roche Ltd., GE HealthCare Technologies, Inc., Horiba, Ltd., Illumina, Inc., Innovative Biochips, LLC, LI-COR, Inc., Luminex Corporation by DiaSorin S.p.A., Merck KGaA, Micronit B.V., Nutcracker Therapeutics, Opteev, PerkinElmer Inc., Phalanx Biotech Group Inc. by WIN Semiconductors Corp., QIAGEN N.V., Sphere Fluidics Limited, Standard BioTools Inc., and Thermo Fisher Scientific Inc..
Market Segmentation & Coverage